Vanguard Personalized Indexing Management LLC Takes $133,000 Position in Teladoc Health, Inc. (NYSE:TDOC)

Vanguard Personalized Indexing Management LLC acquired a new stake in Teladoc Health, Inc. (NYSE:TDOC) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,572 shares of the health services provider’s stock, valued at approximately $133,000.

Several other institutional investors have also bought and sold shares of the company. ICA Group Wealth Management LLC purchased a new stake in shares of Teladoc Health during the fourth quarter worth $28,000. Signaturefd LLC grew its stake in shares of Teladoc Health by 148.7% during the second quarter. Signaturefd LLC now owns 2,868 shares of the health services provider’s stock valued at $28,000 after buying an additional 1,715 shares during the last quarter. International Assets Investment Management LLC bought a new position in shares of Teladoc Health during the second quarter valued at about $29,000. Doheny Asset Management CA bought a new position in shares of Teladoc Health during the second quarter valued at about $46,000. Finally, SageView Advisory Group LLC purchased a new stake in shares of Teladoc Health during the first quarter worth about $48,000. Hedge funds and other institutional investors own 76.82% of the company’s stock.

Teladoc Health Stock Up 8.5 %

TDOC opened at $9.18 on Tuesday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.62 and a current ratio of 1.66. Teladoc Health, Inc. has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The firm’s fifty day moving average is $7.93 and its 200 day moving average is $10.58. The stock has a market cap of $1.57 billion, a price-to-earnings ratio of -6.51 and a beta of 0.90.

Teladoc Health (NYSE:TDOC) last released its earnings results on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. The company had revenue of $642.44 million for the quarter, compared to analysts’ expectations of $649.34 million. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. On average, sell-side analysts forecast that Teladoc Health, Inc. will post -1.18 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have recently weighed in on TDOC shares. JPMorgan Chase & Co. dropped their target price on shares of Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a report on Monday, August 26th. Truist Financial lowered their target price on shares of Teladoc Health from $15.00 to $10.00 and set a “hold” rating for the company in a report on Friday, August 2nd. Piper Sandler lowered their target price on shares of Teladoc Health from $25.00 to $10.00 and set an “overweight” rating for the company in a report on Tuesday, August 6th. Barclays reduced their price target on shares of Teladoc Health from $20.00 to $10.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $10.00 price target on shares of Teladoc Health in a research report on Tuesday, August 20th. Fifteen investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $12.31.

Insiders Place Their Bets

In other news, CEO Laizer Kornwasser sold 10,879 shares of the business’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $88,555.06. Following the sale, the chief executive officer now directly owns 99,929 shares in the company, valued at approximately $813,422.06. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Laizer Kornwasser sold 10,879 shares of the company’s stock in a transaction dated Friday, August 2nd. The shares were sold at an average price of $8.14, for a total transaction of $88,555.06. Following the transaction, the chief executive officer now directly owns 99,929 shares in the company, valued at approximately $813,422.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Mala Murthy sold 8,750 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.16, for a total transaction of $62,650.00. Following the transaction, the chief financial officer now owns 85,767 shares in the company, valued at $614,091.72. The disclosure for this sale can be found here. Insiders have sold a total of 57,377 shares of company stock worth $438,054 in the last 90 days. 0.95% of the stock is currently owned by corporate insiders.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.